Medical technology company iRhythm Technologies (NASDAQ:IRTC) will be reporting results tomorrow afternoon. Here’s what investors should know.
iRhythm beat analysts’ revenue expectations by 3.9% last quarter, reporting revenues of $164.3 million, up 24% year on year. It was a very strong quarter for the company, with a solid beat of analysts’ EPS estimates.
Is iRhythm a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting iRhythm’s revenue to grow 16.4% year on year to $153.6 million, slowing from the 18.4% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.94 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. iRhythm has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 2.4% on average.
Looking at iRhythm’s peers in the healthcare equipment and supplies segment, some have already reported their Q1 results, giving us a hint as to what we can expect. ResMed delivered year-on-year revenue growth of 7.9%, meeting analysts’ expectations, and Penumbra reported revenues up 16.3%, topping estimates by 2.7%. ResMed traded up 10.1% following the results while Penumbra was also up 7.2%.
Read our full analysis of ResMed’s results here and Penumbra’s results here.
Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.6% on average over the last month. iRhythm’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $130.92 (compared to the current share price of $106.64).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.